Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
ClinicalTrials.gov · NCT04216589 · Registry updated: 2024-10-01
- Condition / research focus
- HIV Infections; Non-Alcoholic Fatty Liver Disease
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Countries with listed sites
- Brazil · United States
- Registry dates and results
- Start: 2021-02-19. Completion: 2023-09-15 (may be estimated). Results are posted in this registry.
Products and interventions (1)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide (drug)
Where the study takes place — 9 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Alabama CRS (Site ID: 31788)Birmingham, Alabama, United States